EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis

Hong Zheng, XiaoJiu Zha

ONCOLOGY · 2026-09-10 · 40 (7)

DOI: 10.46883/2026.25921241 ↗
AbstractBibliografische Angaben

Abstract

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer. STRN-ALK fusions are rare among the nonclassical ALK fusion types, and they pose problems diagnostically and therapeutically. A 50-year-old woman had a 2-year history of cough, sputum, and wheeze. Initial workup revealed a severe mixed ventilatory defect, and imaging demonstrated left lung obstruction with mediastinal lymphadenopathy. Bronchoscopy confirmed mucinous adenocarcinoma, and molecular testing revealed a rare STRN-ALK fusion. Because of the patient’s clinical deterioration and concurrent brain metastases diagnosis, ensartinib was started in conjunction with chemotherapy. The patient had a significant improvement in symptoms, including weight gain. Imaging showed a reduction in total tumor burden and no new lesions on follow-up. The results suggested that ensartinib provided central nervous system stability and long-term tumor control. This is unlike prior descriptive accounts of patients with STRN-ALK fusion lung adenocarcinoma.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →